Kidney Failure Prediction: Multicenter External Validation of the KFRE Model in Patients with CKD Stages 3-4 in Peru

Authors:

Bravo-Zúñiga J (0000-0003-2528-6271), nephrologist at Nephrology Department, Hospital Edgardo Rebagliati Martins, EsSalud, Lima, Perú.

Chávez-Gómez R (0000-0003-4919-0098), nephrologist at Nephrology Department, Hospital Edgardo Rebagliati Martins, EsSalud, Lima, Perú.

Soto-Becerra P (0000-0001-5332-9254), associated researcher at Universidad Continental, Huancayo, Perú.

Corresponding author:

Correspondence to Percy Soto-Becerra percys1991@gmail.com

Universidad Continental, Huancayo, Perú.

ABSTRACT

Objectives: To externally validate the 4-variable Kidney Failure Risk Equation (KFRE) in the Peruvian population for predicting kidney failure at 2 and 5 years. **Design:** A retrospective cohort study. **Setting:** 17 primary care centers from the Health's Social Security of Peru. **Participants:** Patients older than 18 years, diagnosed with chronic kidney disease (CKD) stage 3a-3b-4 and 3b-4, between January 2013 and December 2017. Patients were followed until they developed kidney failure, died, were lost, or ended the study (December 31, 2019), whichever came first. **Primary and Secondary Outcome Measures:** Performance of the KFRE model was assessed based on discrimination and calibration measures considering the competing risk of death. **Results:** We included 7519 patients in stages 3a-4 and 2,798 patients in stages 3b-4. The estimated cumulative incidence of kidney failure, accounting for competing event of death, at two years and five years was 1.52% and 3.37% in stages 3a-4 and 3.15% and 6.86% in stages 3b-4. KFRE discrimination at 2 and 5 years was high, with Time-Dependent Area Under the Curve (AUC-td) and C-index > 0.8 for all populations. Regarding calibration in-the-large, the Observed-to-Expected (O/E) ratio and the calibration intercept indicated that KFRE underestimates the overall risk at two years and overestimates it at 5-years in all populations. **Conclusions:** The 4-variable KFRE models have good discrimination but poor calibration in the Peruvian population. The model underestimates the risk of kidney failure in the short term and overestimates it in the long term. Further research should focus on updating or recalibrating the KFRE model to better predict kidney failure in the Peruvian context before recommending its use in clinical practice.

Keywords: Prognostic model, chronic kidney disease, chronic kidney replacement therapy, Kidney Failure Risk Equation

SUMMARY BOXES

What is already known on this topic:

• The Kidney Failure Risk Equation (KFRE) has been externally validated in several
independent studies worldwide.

• Most of these validations have been conducted in North American, European, and Asian
countries.

• There is a notable gap in the literature regarding KFRE validation studies in Latin America,
particularly at the primary care level.

What this study adds:

• This study validates the 4-variable KFRE in Peruvian CKD patients, demonstrating good
discrimination whilst emphasising the need for recalibration to prevent detrimental
patient outcomes.

• Future research should ensure model recalibration, evaluate KFRE's clinical utility, and
investigate broader external validation in diverse populations prior to its implementation
in clinical practice.

INTRODUCTION

Chronic kidney disease (CKD) is a significant global public health issue with a high economic cost for healthcare systems and a continuously increasing disease burden [1,2]. The prevalence of CKD in the general population worldwide is estimated to be over 10% [2–4]. However, the burden of CKD is more pronounced in low- and middle-income countries, where limited resources and a fragmented healthcare system exacerbate the problem [2,5,6]. In Peru, a middle-income country in Latin America, over 2.5 million adults suffer from some degree of CKD, with estimated prevalences in some regions ranging between 16% and 20% of the general population [7–10].

Timely referral of patients with CKD to nephrologists significantly reduces healthcare costs as CKD progresses to kidney failure and death. In healthcare systems with limited established health networks and few nephrology specialists, early referral is vital [11]. To aid in clinical decision-making, CKD progression risk prediction models provide guidance on when referral to nephrologists is necessary, offer counseling on kidney replacement therapy (KRT) options, and aid in planning vascular access to prevent abrupt and unplanned emergency admissions [12,13]. Accurate short-term predictions are particularly important in situations where establishing accurate individualized risk is critical [14–16]. Conversely, long-term predictions may be more informative in identifying patients who need to remain in primary care for secondary prevention, treatment, and follow-up [14–16].

International guidelines recommend using individualized risk prediction models to inform the appropriate time for nephrologist referral and KRT planning (17–20). However, in Peru, recommendations for referral are primarily based on the isolated or combined use of eGFR, albuminuria, or ACR thresholds [21]. These criteria do not employ individualized risks, which may lead to the unnecesary referral of low-risk patients and the failure to refer high-risk patients [17,22].

The Kidney Failure Risk Equation (KFRE) is an individualized risk prediction equation for CKD patients' progression to kidney failure [23]. Some international guidelines have recommended KFRE for CKD management [14,18,19,24]. The KFRE has an 8-variable and 4-variable version, with the latter being an attractive alternative that requires a few easily accessible variables in the Peruvian health system. However, the predictive error of the models can vary significantly between populations, emphasizing the importance of validating their predictive performance in the population where they are to be applied [25–27].

Unfortunately, the lack of external validation studies of KFRE in the Latin American

population, including Peru, has postponed its adoption in local clinical practice.

Therefore, this study aims to validate the 4-variable KFRE model's predictive performance in

a large and diverse sample of insured patients assigned to various health establishments of

the Social Health Insurance (EsSalud) in Lima, Peru, for predicting the risk of kidney failure at

2 and 5 years.

METHODS

Design, Study Population, and Data Source

We conducted a retrospective cohort study following the Transparent Reporting of a

multivariable prediction model for Individual Prognosis Or Diagnosis guidelines (see TRIPOD

checklist in **Supplementary Material**) [27,28] to validate the Kidney Failure Risk Equation

(KFRE) model for predicting the risk of kidney failure at 2- and 5-year horizons in patients

with chronic kidney disease (CKD).

As part of the EsSalud National Kidney Health Plan, the Rebagliati Healthcare Network

established an electronic registry of CKD patients treated at its affiliated health facilities from

primary care until tertiary level. We obtained demographic and clinical data from the

electronic medical records of the EsSalud Hospital Management System and the Chronic

Kidney Disease Management Unit (UMERC) of the Kidney Health Surveillance Subsystem

(VISARE) computer application [29].

The study population included patients aged 18 years or older with CKD between January 1,

2013, and December 31, 2017, treated in 17 primary care healthcare centers in the Rebagliati

Healthcare Network in Lima, Peru. Lima is the capital of Peru and concentrates most insured

patients at national level. We included patients with an estimated glomerular filtration rate

(eGFR) between 15 and 60 ml/min/1.73m², corresponding to categories 3a, 3b, and 4 of the

Kidney Disease Improving Global Outcomes (KDIGO) classification [20], and those who had a

recorded quantifiable albumin-to-creatinine ratio (ACR) measurement taken simultaneously

with eGFR. The date of ACR measurement was the start point for beginning the follow-up

and for predicting the risk of kidney failure using KFRE.

We validated the KFRE models in two populations of interest: (i) a broad population of

patients with CKD stages 3a, 3b, and 4 (3a-4), such as originally was validated, and (ii) a more

specific population with CKD in more advanced stages (3b-4).

Patient and Public Involvement

There was no direct patient and public involvement in the design, conduct, or reporting of

this study.

Sample size

We did not conduct a formal sample size calculation, as we had access to all data collected

routinely. Nevertheless, we were cognisant of the unreliability of performance assessment

with insufficient sample sizes, particularly in the context of a low number of events.

Consequently, we restricted our analysis to clinically relevant subpopulations, ensuring that

each group contained a minimum of 100 events and non-events [27]. Given these

constraints, we deemed it unreliable to analyse groups 3a, 3b, and 4 separately. Instead, we

combined them into subgroups 3a-3b-4 and 3b-4 for the analysis.

Validation Model

Tangri et al. developed the KFRE model in Canada in 2011 to predict kidney failure in

populations with CKD stages 3 to 5 [23]. The model was later recalibrated based on an

extensive meta-analysis that included 31 cohorts from more than 30 countries and over

72,000 participants [30]. The 4-variable KFRE includes age, patient sex, eGFR, and ACR

collected on the same date for each patient and is an attractive alternative since it requires

few variables that are easily accessible in the Peruvian health system. This version has two

prediction horizons: short-term at 2 years and long-term at 5 years (equations in **Table S1**).

Predictors

The four predictors of the 4-variable KFRE are age (years), sex (male/female), eGFR

(ml/min/1.73m^2), and ACR (mg/g) (see **Table S2**). The eGFR was estimated using the 2009

CKD Epidemiology Collaboration (CKD-EPI) formula [20,31] (see **Supplementary Methods –**

section 1.3 for details). The health establishments in the Rebagliati Network have

standardized care protocols for CKD patients, including laboratory procedures, as part of the

Peruvian National Kidney Health Plan. Serum creatinine levels for eGFR estimation were

determined from a blood sample. For ACR calculation, urine creatinine and albumin levels

were determined by quantitative and automated laboratory tests from a random urine

sample. Qualified personnel verified the preanalytical conditions in each hospital. The urine

samples were collected in 10-15 ml bottles and transported between 4 and 8 ºC to the

respective laboratory for daily processing. The entire analytical process followed good

laboratory and analytical quality control practices. We obtained all data on these variables

from UMERC, a computer app designed specifically for this purpose.

Outcome variable

The outcome variable was kidney failure, defined as KRT-treated end-stage renal disease

(ESRD), which in Peru comprises the initiation of hemodialysis or peritoneal dialysis indicated

by a nephrologist and based on clinical parameters of uremia and eGFR < 15ml/min/1.73m^2.

To estimate the observed risk of kidney failure, we considered the competing event of death

without KRT. The data on the date of admission to KRT were obtained from the dialysis

database and were verified in the digital clinical history. The date of death until December

31, 2019, was obtained from the National Registry of Identification and Civil Status (RENIEC)

of Peru.

Follow-up time

We followed patients until they developed kidney failure, death, or censorship, whichever

occurred first. We censored observations until the patient was lost to follow-up or the end of

the study (December 31, 2019). We chose to end the study on this date to avoid having data

from the pandemic, during which the health system collapsed, kidney care services were

affected, and the reliability of the information was altered.

Statistical analysis

Initial data analysis

We performed an initial data analysis to identify implausible extreme values, missing data,

and inconsistencies. Plausible extreme data was retained without any transformation in the

main analysis. Numerical and categorical variables were described using median

(interquartile ranges) and absolute frequencies (percentages), respectively.

Estimate of observed risk

We estimated non-parametric cumulative incidence function (CFI) curves and their 95%

confidence intervals (95% CI) using the Aalen-Johansen estimator [32] for kidney failure and

considering the competing risk of death without kidney failure.

Predictive Performance of KFRE

We estimated the individual predicted risks of developing kidney failure using the 4-variable

KFRE for 2- and 5-year horizons (prediction formulas in **Table S1**). We assessed the

performance of the models based on discrimination and calibration measures [27,28]

according to TRIPOD guidelines. Additionally, we considered the risk of death without kidney

failure and based our analysis workflow on two recently published methodological guides on

external validation of prediction models in the presence of competing risks [33,34].

Discrimination is a relative measure of how well the model distinguishes between patients

with or without the condition of interest [34,35]. To assess discrimination, we estimated the

truncated concordance index (C-index) at 2- and 5-years for each model and the areas under

the ROC time-dependent curves of cumulative sensitivity and dynamic specificity (C/D AUC-

td) [36]. A C-index or C/D AUC-td of 1 indicates perfect discrimination, 0.5 indicates no

discrimination, and values ≥ 0.8 are generally considered appropriate for prognostic models

[35]. We accounted for the competing risk for death without kidney failure by censoring

patients who die at infinite, indicating that they may not develop kidney failure in the future

[33,34].

Calibration is a measure that indicates how well the absolute predicted risks agree with the

observed risks. These observed risks were estimated using CFI to takte into account the

competing risk of death without kidney failure [33,34]. We assessed calibration-in-the-large

using the observed to expected results (O/E), a measure of mean calibration, and the

calibration intercept, a measure of weak calibration. We also assessed weak calibration

through calibration slope. Moderate calibration was assessed inspecting calibration plots.

We estimated the ratio of observed to expected results (O/E). An O/E indicates perfect global

calibration, an O/E > 1 indicates an underestimation of the average risk, and an O/E < 1

reveals an overestimated of the average risk. The calibration intercept is another measure

that evaluates the average over or underestimation that we estimate in this study. An

intercept of 0 indicates perfect agreement between the predicted and observed risk average.

An intercept significantly < 0 indicates an overestimation, and an intercept > 0 indicates an

underestimation of the risk average. We also estimated the calibration slope. A slope of 1

reflects ideal agreement. A slope less than 1 indicates that the predicted risks are too

extreme (very high and low), while a slope greater than 1 indicates that the predictions do

not show enough variation. To formally test statistical evidence of miscalibration, we first

performed a Wald test of the joint contribution of the intercept and slope, as previously

described for calibration models in prediction models [33,34].

Calibration plots allow calibration to be assessed in detail by comparing observed individual

risks with those predicted. A curve exactly following the 45º straight line would indicate a

perfect situation named strong calibration that is ideal and utopic. A more realistic goal is to

assess if the curve is close to the diagonal indicating moderate calibration. We plotted

calibration curves estimated by smoothed local linear regression (loess) based on

pseudovalues obtained from cumulative incidence estimates that account for the competing

risk of death [33,34,37].

Sensitivity analysis

We perform two sensitivity analyses:

1) The same analysis approach after eliminating the extreme values of ACR by winzoring at

the 1st and 99th percentiles of the distribution of this variable.

2) A predictive performance analysis ignoring competitive risk. This analysis relied extensively

on the methodology described by McLernon DJ et al [37].

General approach

The data preparation and all the analyzes were carried out with the statistical program R

version 4.2.1 for Windows 11 x 64 bits. As there were no missing data in critical variables, all

analysis were case-complete. Except for the C-index, all the 95% confidence interval (CI) were

Wald-type [33,34]. The 95% CI for C-index was obtained using the percentile bootstrap

method using 1000 bootstrapped samples [33,34].

RESULTS

Study population

Among the 22,745 patients screened between January 1, 2013, and December 31, 2017, at

17 hospitals within the Rebagliati Healthcare Network in Lima, only 13,890 had complete ACR

data, of which 7,519 patients were eligible due to a diagnosis of CKD 3a-4, while 2,798 were

eligible for the CKD 3b-4 subgroup (**Figure 1**). All eligible patients had complete data on

outcome, age, sex. The number of events of outcome was over 100 in all populations, except

for kidney failure at 2-years in patients with CKD 3b-4 stages (n = 88), and thus estimates in

this group should be interpreted with caution.

269         *[Figure 1]*

271 Within the CKD 3a-4 subgroup, 114 patients developed kidney failure within 2 years, while

272 239 developed kidney failure within 5 years. Moreover, 563 patients died without

273 experiencing kidney failure within 2 years, and 1,400 patients died without experiencing

274 kidney failure within 5 years. Within the CKD 3b-4 group, 88 patients developed kidney

275 failure within 2 years, and 182 developed kidney failure within 5 years, while 300 patients

276 died without experiencing kidney failure within 2 years, and 683 patients died without

277 experiencing kidney failure within 5 years. The median observation time was 4.9 years, and

278 the maximum follow-up was 7.8 years in the CKD 3a-4 group.

280 **Table 1** summarizes the baseline characteristics of the study population, and **Supplementary**

281 **Results** provide a breakdown of the study population's characteristics according to kidney

282 failure at 2 and 5 years for CKD 3a-4 (see **Table S3**) and CKD 3b-4 (see **Table S4**), respectively.

283 The numbers of cases of kidney failure at 2 years were low for the subpopulations with

284 stages 3a (n = 26), 3b (n = 36), and 4 (n = 52) (see **Table S5**). Similarly, the 5-year case

285 numbers were low for subpopulations with stages 3a (n = 57), 3b (n = 81), and 4 (n = 101)

286 (**Table S5**). Therefore, evaluating predictive performance in these specific subgroups was

287 unreliable. The distribution of patients in stages 3a-4 and 3b-4 who entered the analysis in

288 each of the 17 health facilities of the EsSalud Rebagliati Network is shown in **Table S6** and

289 **Table S7** of the supplementary material.

290         *[Table 1]*

292 **Observed and predicted risk of kidney failure**

293 **Figure 2** displays the observed risk of kidney failure and death without kidney failure for both

294 study populations. The 2- and 5-year observed risks of kidney failure in patients with CKD

295 stages 3a-4 were 1.52% and 3.37%, respectively (**Table S7**). In patients with CKD 3b-4, the 2-

296 and 5-year observed risks of kidney failure were 3.15% and 6.87%, respectively (**Table S8**).

297 The distribution of the 2- and 5-year predicted risk by KFRE are shown in **Figure S1**.

298         *[Figure 2]*

300 **KFRE predictive performance**

301 The Kidney Failure Risk Equation (KFRE) demonstrated good discriminatory ability across all

302 time horizons and study populations, as evidenced by C-index and C/D AUC-td values

303 exceeding 0.8 (**Table 2**). In contrast, miscalibration tests shows that data had low

304 compatibility with good calibration of KFRE at all-time horizons and groups (all p-values
305 ≤0.001) proportioning evidence of misscalibration of the model (**Table 2**).
306 *[Table 2]*
307
Regarding calibration in the large, for patients with CKD stages 3a-4, the 2-year average
observed risk of kidney failure was 1.52%, while the average risk predicted by KFRE was
lower at 0.96%, yielding an O/E ratio of 1.57 (95% CI 1.39 to 1.76). This indicates an overall
underestimation of the actual 2-year risk of kidney failure by the model. In patients with CKD
stages 3b-4, a similar pattern of underestimation of the actual 2-year risk of kidney failure
was observed (O/E ratio: 1.33; 95% CI 1.13 to 1.54). In contrast, the imprecision of the
calibration intercepts made these estimates less useful for evaluating the calibration in-the-
large of KFRE at 2 years for both populations.
316
For the 5-year KFRE model, evidence of poor calibration in the large was also observed,
although in the opposite direction, suggesting an overprediction. In this case, the O/E ratio
was less useful for evaluating the long-term calibration of KFRE due to the high imprecision of
its estimates. However, the calibration intercepts revealed that, on average, KFRE
overestimated the actual 5-year risk of kidney failure for both the CKD stages 3a-3b-4
population (calibration intercept: -0.26; 95% CI -0.45 to -0.07) and the CKD stages 3b-4
subgroup (calibration intercept: -0.29; 95% CI -0.48 to -0.1) (**Table 2**).
324
KFRE also showed evidence of poor weak calibration. At 2-years, there was statistical
evidence of very extreme predictions (i.e., very high and low) for the population with CKD
stages 3a-3b-4 (calibration slope: 0.79; 95% CI 0.61 to 0.96) and CKD stages 3b-4 (calibration
slope: 0.82; 95% CI 0.6 to 1.03), although the latter with an uncertainty associated with the
estimate in the borderline. In the case of the 5-year KFRE, very extreme predictions were also
found in both groups, with calibration slopes of 0.75 (95% CI 0.65 to 0.86) for the population
with CKD stages 3a-3b-4 and 0.79 (95% CI 0.65 to 0.92) for the population with CKD stages
3b-4 (**Table 2**).
333
Regarding evidence of poor moderate calibration, the calibration curves (**Figure 3**) revealed
that the underestimation of actual risk at 2-years was mainly concentrated in patients with
predicted risk less than 0.3-0.4 for both subgroups with CKD stages 3a-4 and CKD stages 3b-4
(**Figures 3A** and **3C**). Conversely, the overestimation of the actual risk of renal failure at 5-

years mainly occurred in individuals with risk predicted by KFRE greater than 0.2 in both

subgroups with CKD stages 3a-4.

[Figure 3]

Sensitivity analysis: Impact of outliers in ACR

The distribution of the four variables constituting the KFRE equation and the distribution of

risks predicted by KFRE are depicted in **Figure S1** and **Figure S2**, respectively. We observed

that the ACR variable exhibited very extreme values (**Figure S2 C** and **Figure S2 D**), prompting

a sensitivity analysis to evaluate the robustness of our predictive performance assessment

after mitigating the influence of these extreme values. Winsorisation of ACR's extreme values

was applied at its 1st and 99th percentiles, and risks predicted by KFRE were recalculated

using the winsorised ACR variable. Despite observing notable changes in ACR's distribution

after winsorisation (**Figure S3**), the distribution of risks predicted by KFRE in the original data

did not exhibit discernible alterations (**Figure S4**). Median and mean values of risks predicted

by KFRE before and after winsorisation were strikingly similar, as were variability measures

such as standard deviation, interquartile range, and range (**Table S10**). As anticipated, the

predictive performance of KFRE on the winsorised data closely resembled those obtained on

the original data (**Table S11** and **Figure S5**).

Sensitivity analysis: Predictive performance assessment ignoring competing risk

We assessed the extent to which the predictive performance results differed when not

accounting for competing risks. We found that the 2-year incidence of kidney failure in CKD

stages 3a-4, when not considering competing risk, was 1.58%, only slightly higher than when

accounting for competing risk (1.52%) (**Fig S6**). At 5 years, these differences become more

pronounced but remain relatively small, with a 3.37% incidence when considering competing

risk and 4.24% when not considering competing risk. In the CKD stages 3b-4 population, the

5-year differences are only about 2% (6.89% when considering competing risk vs. 8.99%

when not considering competing risk) (**Fig S6**). Consequently, the assessment of KFRE's

predictive performance without considering competing risks also found that KFRE was

miscalibrated (**Table S12** and **Fig S6**); however, notably, the magnitude of miscalibration was

substantially smaller when ignoring competing risks compared to when competing risks were

considered (**Fig S7**).

DISCUSSION

Principal findings

We conducted an independent external validation of the 4-variable KFRE for kidney failure

prognosis at 2- and 5-years in patients with CKD at stages 3a-4 and 3b-4 from Peru. Despite

showing good discrimination to predict kidney failure, KFRE exhibited poor calibration.

Poor calibration in the large resulted in the model underestimating the average actual risk of

developing kidney failure in the short term (2-years) and overestimating the average actual

risk of kidney failure in the long term (5-years) in patientis with CKD stages 3a-4. This pattern

of poor calibration was also observed in the subgroup of patients with CKD stages 3b-4. KFRE

also had poor weak calibration manifested as very extreme predictions, while poor moderate

calibration was evident in the underestimation of actual short-term risk in patients with

KFRE-predicted risks below 0.3-0.4 and overestimation of individual long-term risks, primarily

in individuals with a KFRE-predicted risk greater than 0.2.

Comparison with previous literature

It is noteworthy that the Kidney Failure Risk Equation (KFRE) has been externally validated in

several independent external studies worldwide [16,23,30,38–49]. However, the majority of

these validations have been conducted in North American [23,30,39,41,43–48] or European

countries [16,30,40,49], with more recent validations taking place in other Asian countries

[38,42]. Upon conducting a systematic literature search, we were unable to identify any

published external validation studies of KFRE specifically within the Latin American

population at primary care level. A single study did incorporate a Latin American cohort,

comprising Chilean and Brazilian patients; however, extrapolating the study data to the

current chronic kidney disease (CKD) patient population presents a challenge, as the cohort's

patient recruitment took place between 1996 and 1998 [30]. In the past two decades,

significant advancements in CKD management, including diagnostic methods, treatment

strategies, and patient care, have contributed to improved patient outcomes. As a result, the

external validation results from the Chilean and Brazilian patient cohort [30] may no longer

accurately represent current CKD populations in these countries. This emphasises a notable

gap in the literature and underscores the need for updated KFRE validation studies in Latin

America, ensuring its applicability and accuracy across diverse regional populations.

In line with prior research, the non-North American versions of the KFRE models at 2- and 5-

year intervals exhibited good discrimination in our study and across diverse population

groups from countries [16,30,38,40,42,49]. The initial external validation of the non-North

American KFRE, a meta-analysis comprising 13 cohorts including Chilean and Brazilian

patients [30], reported pooled C-statistics of 0.9 and 0.88 for predicting 2- and 5-year kidney

failure, respectively [30]. A more recent study observed lower discrimination values, with C-

indexes ranging from 0.76-0.84 for 2-year KFRE and 0.75-0.81 for 5-year KFRE in cohorts from

Germany, Italy, the Netherlands, Poland, Switzerland, and the United Kingdom, none of

which included Latin American countries [16]. Despite the lower values in the recent study,

the discrimination remained good. These findings are consistent with other studies reporting

C-index values greater than 0.8 for the non-North American KFRE at 2- and 5-years

[38,40,42,49].

In contrast to discrimination, our study's calibration assessment results differ from the initial

study that recalibrated and validated KFRE for non-North American populations [30].

Although the few studies that assess calibration of the non-North American version of KFRE

have reported poor calibration [33,40,42,49], most primarily focus on moderate calibration

using calibration curves, with limited attention given to calibration in the large or weak

calibration. Our findings for moderate calibration are in line with previous studies that

identified overprediction of kidney failure risk at 5 years [33,40,42,49], particularly in

individuals with high predicted risk groups (>0.3 to 0.4) [42,49].

On the other hand, the 2-year results display greater heterogeneity among existing studies:

some cohorts show good calibration [33,42], others overpredict risk in high- and low-risk

groups [40]. In our study, we found that KFRE exhibits an opposite pattern of underprediction

at 2 years. Regarding calibration in the large, only Ramspek et al. assessed this aspect, finding

an overprediction of the average 5-year risk by >10% while observing good calibration in the

large at 2 years. This contrasts with our study, which also identified underestimation of the

actual average risk by KFRE at 2 years in patients with CKD 3a-4 and CKD 3b-4.

Differences in severity or stages between the initial study validation and ours could explain

these discrepancies. In our study, for example, more than half of patients were classified as

having moderate stage of severity of CKD (stage G3a), and we did not include any patients

with advanced CKD (stage G5) (**Table 1**). In comparison, Tangri et al. included stage 5 CKD

patients, although it is difficult to assess the impact of these differences as Tangri et al. did

not report information on the stage distribution of their study population. We also did not

observe significant differences in eGFR and albuminuria distributions, recognised markers for

kidney failure prognosis [47] in patients with CKD (see **Table S13**). The initial study reported

mean (standard devaition) values of 47 ml/min/1.73m^2 (12 ml/min/1.73m^2 ml/min/1.73m^2)

for eGFR and a 34% of prevalence of albuminuria for their non-North American population,

while our study reported similar values of 46.2 ml/min/1.73m^2 (9.8 ml/min/1.73m^2) and

36.5%, respectively (**Table S13**). The actual event risk may also explain the model's

miscalibration. Kidney failure incidence rates suggest that risk of kidney failure was lower in

the patients with CKD stages 3a-4 of our study (7.4 per 1000 person-years compared to 9.2

per 1000 person-years).

Another explanation for the pattern of overprediction we found in the long term for the KFRE

model, especially in advanced CKD populations [43–45], is partly due to not accounting for

death without kidney failure as a competing risk [33,34]. This competing risk is crucial for

patients with advanced CKD, especially in frail or older populations requiring long-term

predictions with more frequent death events [50]. Most existing models censor patients who

die, leading to overestimation of the actual risk [51]. Ramspek et al. [16] and Ravani et al.

[52] found that KFRE overestimated the actual average risk of terminal CKD by 10-18% and 1-

27% at 5 years, respectively, with overestimation increasing over time among high-risk

individuals atributable to competing event. By this reason, we considered the competing risk

of death without kidney failure in our study. Initial study validating KFRE for non-North

American populations also evaluated the impact of competing risk but found no significant

differences.

In our study involving patients with CKD stages 3a-4, 7.5% died without kidney failure at 2

years of follow-up, and 20.5% at 5 years (**Table S8**). Conversely, the cumulative incidence of

kidney failure was low, with 1.5% at two years and 3.4% at 5 years. This demonstrates the

relatively minor impact of competing risk at 2 years, which becomes substantially more

significant at 5 years. Even without considering competing risk, the Cox analysis revealed

miscalibration, displaying the same patterns as the competing risk analysis, although the

degree of miscalibration would have been less pronounced.

It is important to note that, while differences exist between using Cox and competing risk

analyses at the 2-year horizon, these disparities are minimal in our study. In contrast, at 5

years, marked differences emerge, with the Cox analysis evidently biasing the performance

evaluation. Therefore, we chose to report the competing risk analysis as our primary method

and the Cox analysis as secondary. This approach better reflects the increasing impact of

competing risk when the incidence of the competing event (death without renal failure)

becomes more frequent, as observed in the 5-year assessment.

Strengths and limitations of this study

This study boasts several strengths and represents, as far as we know, the second

investigation of the Kidney Failure Risk Equation (KFRE) in Latin America, further expanding

on the limited research in this region. The only previous study in the region was a meta-

analysis that validated the original equation for non-North American populations, which

included cohorts from Chile and Brazil [30]. However, these cohorts are no longer current, as

they date back to 1996-1998 [30]. By providing the first external validation of KFRE in Peru,

this study fills a critical gap in the literature and offers valuable insights into the applicability

of KFRE in a contemporary Latin American context. Drawing from a retrospective cohort of

over 7,000 patients across 17 primary and secondary care EsSalud health establishments in

Lima, the capital city accounting for a third of Peru's population, the findings have a certain

degree of generalisability. The results are particularly relevant for EsSalud-insured patients in

Lima, who make up a significant proportion of chronic kidney disease (CKD) patients in the

country.

Employing robust statistical methods and sound analytical techniques, the study

appropriately assesses the performance of KFRE in predicting kidney failure while considering

the competing risk of death without kidney failure. This approach helps avoid overestimation

of the observed risk and reduces bias in performance assessment, as opposed to solely

relying on Cox methods, which were originally considered in the study protocol [33,34,50,53].

The decision to use this competing risk approach as a primary analysis, with Cox methods

employed in a sensitivity analysis, was informed by contemporary evidence demonstrating

that accounting for competing risks offers a less biased and more accurate estimation of the

actual kidney failure risks [33,52]. As such, this study adheres to best practices in the field

and contributes essential knowledge regarding KFRE's performance in Peru and Latin America

more broadly.

Although our study presents valuable findings; it is important to acknowledge several

limitations. Firstly, we utilized secondary data routinely recorded by multiple evaluating

clinicians across 17 healthcare centers in Lima. On one hand, using routine clinical data has

the advantage of potentially reflecting the model's performance more accurately in real-

world clinical practice. However, despite standardization of laboratory measurements as part

of the National Kidney Program in Peru, clinical registries are inherently susceptible to errors

in data recording, thereby introducing the potential for measurement error.

Another limitation stems from our use of RRT initiation as an indicator of kidney failure in

patients. This approach carries the risk of misclassification for patients who may have opted

for conservative management. Nevertheless, it is worth noting that conservative

management is relatively rare in Peru. Furthermore, access to RRT for EsSalud beneficiaries in

Lima is fully covered by EsSalud, which bears the entire cost reducing the risk of not access to

RRT, specially in Lima. These factors imply that the risk of bias might be reduced;

nevertheless, we still regard this as a significant limitation that should be appropriately

addressed in future prospective studies.

Lastly, although the similarities among EsSalud service networks in Lima may support the

notion that our findings could be generalizable to other networks in the city, it is crucial to

recognize that Lima is not representative of the entirety of Peru, and EsSalud is not the sole

healthcare system in the country [54,55]. Significant disparities exist in healthcare services

provided outside Lima and between different healthcare systems, such as Comprehensive

Health Insurance and the Health of the Armed and Police Forces. These variations may

influence KFRE's predictive performance, necessitating specific external validation studies in

these populations due to the distinct differences among Peruvian health subsystems.

Implications for clinical practice

The observed differences in KFRE model performance among various cohorts highlight the

necessity of broadening external validation across diverse populations and settings [25].

Although our study demonstrates KFRE's capacity to effectively discriminate between

patients who will develop kidney failure at 2 and 5 years, it also reveals the model's

shortcomings in accurately predicting individual risks, underestimating them in the short

term and overestimating them in the long term. Sole reliance on KFRE's discrimination ability

may have adverse implications for patients. Given our findings that short-term

overestimation of kidney failure risk occurs in patients with low predicted risk and long-term

underestimation occurs in those with high predicted risk, this pattern of poor moderate

calibration could result in detrimental patient outcomes.

For example, overestimation of risk (overprediction) in patients with a lower true long-term

progression risk may lead to unnecessary referrals for dialysis preparation, provoking

unwarranted anxiety for patients and potentially increasing the risk of death from non-kidney

failure causes, such as preventable cardiovascular events, if the patient had remained at the

primary care level. In contrast, underestimation of risk (underprediction) in patients with a

higher true short-term progression risk due to a miscalibrated KFRE might cause unnecessary

delays in their referral and preparation for dialysis.

Future research

Future research should focus on ensuring model recalibration for clinically relevant

populations in Peru, considering our findings that reveal KFRE miscalibration for EsSalud

patients in Lima. It is imperative that external validation and recalibration assessments

expand to a national level, encompassing the broader EsSalud population. This evidence

could expedite the incorporation of KFRE into EsSalud's clinical practice guidelines.

In concurrence with the recommendations previously put forward by Ramspek et al. [33], it is

essential to examine the influence of patient mix heterogeneity on model performance, such

as through regional comparisons within Peru. This will help in understanding KFRE's

limitations and proposing specific recalibrations to enhance performance at the local level.

When conducting external validation and recalibration for these new populations,

researchers should account for competitive risk. Further studies should assess KFRE's clinical

utility and determine optimal risk thresholds, if necessary, for informed decision-making

while taking clinical relevance into account. Moreover, research should evaluate the impact

of KFRE use on significant patient and healthcare system outcomes, including dialysis

complications, mortality, and emergency admissions, among others. Notably, these

investigations should be conducted within the context of clinical trials.

Conclusions

The KFRE model using four variables demonstrated good discrimination at 2 and 5 years for

patients with CKD stages 3a-3b-4 and CKD stages 3b-4. However, our study also found that

the KFRE model was miss calibrated, underestimating short-term risks, and overestimating

long-term risks. Despite its great discriminative capacity, the KFRE model should be

recalibrated before being recommended for use in clinical practice guidelines for the

Peruvian population. In light of this evidence, Latin American countries should consider

externally validating and recalibrating this model before recommending its use in clinical

practice.

CONTRIBUTORS

JBZ served as the principal investigator, conceived the study concept, developed the proposal, contributed to the study design, coordinated the project, and participated in drafting the manuscript. RCG co-authored the proposal, contributed to the study design, oversaw data acquisition and preprocessing, and assisted in drafting the manuscript. PSB co-authored the propoposal, contributed to the study design, was responsible for cleaning the raw data, conducting the analysis, and preparing the manuscript. JBZ and PSB serve as guarantors, ensuring the integrity of the study. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. The authors would like to acknowledge the methodological advisoring of the Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, during the initial stages of the project, through its Personalised Mentoring Programme 2020, in the development of this study.

FUNDING

This study was entirely self-funded by the authors and did not receive any external financial support.

ETHICAL APPROVAL

The Research Ethics Committee of the Edgardo Rebagliati National Hospital approved this study (575-GRPR-ESSALUD-2021). Because all the data from clinical registries were anonymized before being processed for the research, the ethics committee accepted the waiver of informed consent from the patients.

COMPETING INTEREST

JBZ and RCG are full-time employees of EsSalud, and PSB has received consultancy fees from EsSalud. However, the authors affirm that their respective affiliations with EsSalud have not influenced any aspect of the study, including study design, data collection, analysis, interpretation, or manuscript preparation. The authors declare that there are no other competing interests or potential conflicts of interest related to the content of this manuscript.

DATA SHARING

The analysis code essential for the replication of study findings can be accessed at this link: https://github.com/psotob91/kfre-ckd-reba-peru. As per the privacy policies of EsSalud, the

minimal data set is not open to public access. However, we are amenable to providing the

anonymised data upon receipt of a reasonable request directed to the corresponding author

(percys1991@gmail.com).

TRANSPARENCY DECLARATION

JBZ and PSB, as the manuscript's guarantors, affirm that the manuscript presents an honest,

accurate, and transparent account of the study reported. They confirm that no significant

aspects of the study have been omitted, and any discrepancies from the planned study have

been duly explained.

REFERENCES

Xie Y, Bowe B, Mokdad AH, *et al.* Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. *Kidney Int* 2018;**94**:567–81. doi:10.1016/j.kint.2018.04.011

Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. *Kidney Int Suppl* 2022;**12**:7–11. doi:10.1016/j.kisu.2021.11.003

Hill NR, Fatoba ST, Oke JL, *et al.* Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. *PloS One* 2016;**11**:e0158765. doi:10.1371/journal.pone.0158765

Sundström J, Bodegard J, Bollmann A, *et al.* Prevalence, outcomes, and cost of chronic kidney disease in a contemporary population of 2·4 million patients from 11 countries: The CaReMe CKD study. *Lancet Reg Health – Eur* 2022;**20**. doi:10.1016/j.lanepe.2022.100438

Stanifer JW, Muiru A, Jafar TH, *et al.* Chronic kidney disease in low- and middle-income countries. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc* 2016;**31**:868–74. doi:10.1093/ndt/gfv466

Suriyong P, Ruengorn C, Shayakul C, *et al.* Prevalence of chronic kidney disease stages 3–5 in low- and middle-income countries in Asia: A systematic review and meta-analysis. *PLOS ONE* 2022;**17**:e0264393. doi:10.1371/journal.pone.0264393

Francis ER, Kuo C-C, Bernabe-Ortiz A, *et al.* Burden of chronic kidney disease in resource-limited settings from Peru: a population-based study. *BMC Nephrol* 2015;**16**:114. doi:10.1186/s12882-015-0104-7

Bravo-Zúñiga J, Gálvez-Inga J, Carrillo-Onofre P, *et al.* Early detection of chronic renal disease: coordinated work between primary and specialized care in an ambulatory renal network of Peru. *J Bras Nefrol Orgao Of Soc Bras E Lat-Am Nefrol* 2019;**41**:176–84. doi:10.1590/2175-8239-JBN-2018-0101

Herrera-Añazco P, Taype-Rondan A, Lazo-Porras M, *et al.* Prevalence of chronic kidney disease in Peruvian primary care setting. *BMC Nephrol* 2017;**18**:246. doi:10.1186/s12882-017-0655-x

Loza Munarriz CA, Ramos Muñoz WC. *Análisis de la situación de la enfermedad renal crónica en el Perú, 2015*. 1ª. Lima 11, Peru: : Dirección General de Epidemiología, Ministerio de Salud del Perú 2016. https://www.gob.pe/institucion/minsa/informes-publicaciones/285012-analisis-de-la-situacion-de-la-enfermedad-renal-cronica-en-el-peru-2015

Martínez-Castelao A, Soler MJ, Górriz Teruel JL, *et al.* Optimizing the timing of nephrology referral for patients with diabetic kidney disease. *Clin Kidney J* 2021;**14**:5–8. doi:10.1093/ckj/sfaa125

Lerner B, Desrochers S, Tangri N. Risk Prediction Models in CKD. *Semin Nephrol* 2017;**37**:144–50. doi:10.1016/j.semnephrol.2016.12.004

13　Wojciechowski P, Tangri N, Rigatto C, *et al.* Risk Prediction in CKD: The Rational
Alignment of Health Care Resources in CKD 4/5 Care. *Adv Chronic Kidney Dis*
2016;**23**:227–30. doi:10.1053/j.ackd.2016.04.002

14　Eckardt K-U, Bansal N, Coresh J, *et al.* Improving the prognosis of patients with severely
decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease:
Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*
2018;**93**:1281–92. doi:10.1016/j.kint.2018.02.006

15　Chapter 2: Definition, identification, and prediction of CKD progression. *Kidney Int Suppl*
2013;**3**:63–72. doi:10.1038/kisup.2012.65

16　Ramspek CL, Evans M, Wanner C, *et al.* Kidney Failure Prediction Models: A
Comprehensive External Validation Study in Patients with Advanced CKD. *J Am Soc*
Nephrol JASN 2021;**32**:1174–86. doi:10.1681/ASN.2020071077

17　Oliva-Damaso N, Delanaye P, Oliva-Damaso E, *et al.* Risk-based versus GFR threshold
criteria for nephrology referral in chronic kidney disease. *Clin Kidney J* 2022;**15**:1996–
2005. doi:10.1093/ckj/sfac104

18　*Chronic kidney disease: assessment and management.* London: : National Institute for
Health and Care Excellence (NICE) 2021.
http://www.ncbi.nlm.nih.gov/books/NBK574714/ (accessed 12 Jan 2023).

19　Farrington K, Covic A, Aucella F, *et al.* Clinical Practice Guideline on management of older
patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m2).
Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc 2016;**31**:ii1–66.
doi:10.1093/ndt/gfw356

20　Levin A, Stevens PE, Bilous RW, *et al.* Kidney disease: Improving global outcomes (KDIGO)
CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and
management of chronic kidney disease. *Kidney Int Suppl* 2013;**3**:1–150.
doi:10.1038/kisup.2012.73

21　Bravo-Zúñiga J, Hinostoza-Sayas J, Goicochea Lugo S-, *et al.* Guía de práctica clínica para
el tamizaje, diagnóstico y manejo de la enfermedad renal crónica en estadios 1 al 3 en el
Seguro Social del Perú (EsSalud). *Acta Médica Peru* 2020;**37**:518–31.
doi:10.35663/amp.2020.374.1843

22　Bhachu HK, Fenton A, Cockwell P, *et al.* Use of the kidney failure risk equation to inform
clinical care of patients with chronic kidney disease: a mixed-methods systematic review.
BMJ Open 2022;**12**:e055572. doi:10.1136/bmjopen-2021-055572

23　Tangri N, Stevens LA, Griffith J, *et al.* A predictive model for progression of chronic kidney
disease to kidney failure. *JAMA* 2011;**305**:1553–9. doi:10.1001/jama.2011.451

24　Chan CT, Blankestijn PJ, Dember LM, *et al.* Dialysis initiation, modality choice, access, and
prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO)
Controversies Conference. *Kidney Int* 2019;**96**:37–47. doi:10.1016/j.kint.2019.01.017

25　Ramspek CL, Jager KJ, Dekker FW, *et al.* External validation of prognostic models:
what, why, how, when and where? *Clin Kidney J* 2021;**14**:49–58. doi:10.1093/ckj/sfaa188

26   Bleeker SE, Moll HA, Steyerberg EW, *et al.* External validation is necessary in prediction
research: a clinical example. *J Clin Epidemiol* 2003;**56**:826–32. doi:10.1016/s0895-
4356(03)00207-5

27   Moons KGM, Altman DG, Reitsma JB, *et al.* Transparent Reporting of a multivariable
prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and
elaboration. *Ann Intern Med* 2015;**162**:W1-73. doi:10.7326/M14-0698

28   Collins GS, Reitsma JB, Altman DG, *et al.* Transparent reporting of a multivariable
prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement.
BMC Med 2015;**13**:1. doi:10.1186/s12916-014-0241-z

29   Oficina de Gestión y Desarrollo de Salud renal - EsSalud. Directiva de la Gerencia Central
de Prestaciones de Salud N° 03-GCPS-ESSALUD-2012: Subsistema de Vigilancia de Salud
Renal (VISARE) - ESSALUD. 2012.

30   Tangri N, Grams ME, Levey AS, *et al.* Multinational Assessment of Accuracy of Equations
for Predicting Risk of Kidney Failure: A Meta-analysis. *JAMA* 2016;**315**:164–74.
doi:10.1001/jama.2015.18202

31   Levey AS, Stevens LA, Schmid CH, *et al.* A New Equation to Estimate Glomerular Filtration
Rate. *Ann Intern Med* 2009;**150**:604–12.

32   Aalen OO, Johansen S. An Empirical Transition Matrix for Non-Homogeneous Markov
Chains Based on Censored Observations. *Scand J Stat* 1978;**5**:141–50.

33   Ramspek CL, Teece L, Snell KIE, *et al.* Lessons learnt when accounting for competing
events in the external validation of time-to-event prognostic models. *Int J Epidemiol*
2022;**51**:615–25. doi:10.1093/ije/dyab256

34   Geloven N van, Giardiello D, Bonneville EF, *et al.* Validation of prediction models in the
presence of competing risks: a guide through modern methods. *BMJ* 2022;**377**:e069249.
doi:10.1136/bmj-2021-069249

35   Riley RD, Windt D van der, Croft P, editors. *Prognosis research in healthcare: concepts,*
methods, and impact. First edition. Oxford: : Oxford University Press 2019.

36   Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in
medical research: current methods and applications. *BMC Med Res Methodol*
2017;**17**:53. doi:10.1186/s12874-017-0332-6

37   McLernon DJ, Giardiello D, Van Calster B, *et al.* Assessing Performance and Clinical
Usefulness in Prediction Models With Survival Outcomes: Practical Guidance for Cox
Proportional Hazards Models. *Ann Intern Med* 2023;**176**:105–14. doi:10.7326/M22-0844

38   Wang Y, Nguyen FNHL, Allen JC, *et al.* Validation of the kidney failure risk equation for
end-stage kidney disease in Southeast Asia. *BMC Nephrol* 2019;**20**:451.
doi:10.1186/s12882-019-1643-0

39   Thanabalasingam SJ, Iliescu EA, Norman PA, *et al.* Independent External Validation and
Comparison of Death and Kidney Replacement Therapy Prediction Models in Advanced
CKD. *Kidney Med* 2022;**4**:100440. doi:10.1016/j.xkme.2022.100440

40 Major RW, Shepherd D, Medcalf JF, *et al.* The Kidney Failure Risk Equation for prediction
of end stage renal disease in UK primary care: An external validation and clinical impact
projection cohort study. *PLoS Med* 2019;**16**:e1002955.
doi:10.1371/journal.pmed.1002955

41 Hundemer GL, Tangri N, Sood MM, *et al.* Performance of the Kidney Failure Risk
Equation by Disease Etiology in Advanced CKD. *Clin J Am Soc Nephrol CJASN*
2020;**15**:1424–32. doi:10.2215/CJN.03940320

42 Kwek JL, Pang HQJ, Li H, *et al.* Validation of the kidney failure risk equation in predicting
the risk of progression to kidney failure in a multi-ethnic Singapore chronic kidney
disease cohort. *Singapore Med J* 2022;**63**:313–8. doi:10.11622/smedj.2020170

43 Peeters MJ, van Zuilen AD, van den Brand JAJG, *et al.* Validation of the kidney failure risk
equation in European CKD patients. *Nephrol Dial Transplant Off Publ Eur Dial Transpl*
Assoc - Eur Ren Assoc 2013;**28**:1773–9. doi:10.1093/ndt/gft063

44 Potok OA, Nguyen HA, Abdelmalek JA, *et al.* Patients,' Nephrologists,' and Predicted
Estimations of ESKD Risk Compared with 2-Year Incidence of ESKD. *Clin J Am Soc Nephrol*
CJASN 2019;**14**:206–12. doi:10.2215/CJN.07970718

45 Whitlock RH, Chartier M, Komenda P, *et al.* Validation of the Kidney Failure Risk Equation
in Manitoba. *Can J Kidney Health Dis* 2017;**4**:2054358117705372.
doi:10.1177/2054358117705372

46 Grams ME, Sang Y, Ballew SH, *et al.* Predicting timing of clinical outcomes in
patients with chronic kidney disease and severely decreased glomerular filtration rate.
Kidney Int 2018;**93**:1442–51. doi:10.1016/j.kint.2018.01.009

47 Naranjo FS, Sang Y, Ballew SH, *et al.* Estimating Kidney Failure Risk Using Electronic
Medical Records. *Kidney360* 2021;**2**:415–24. doi:10.34067/KID.0005592020

48 Bundy JD, Mills KT, Anderson AH, *et al.* Prediction of End-Stage Kidney Disease Using
Estimated Glomerular Filtration Rate With and Without Race : A Prospective Cohort
Study. *Ann Intern Med* 2022;**175**:305–13. doi:10.7326/M21-2928

49 Marks A, Fluck N, Prescott GJ, *et al.* Looking to the future: predicting renal replacement
outcomes in a large community cohort with chronic kidney disease. *Nephrol Dial*
Transplant 2015;**30**:1507–17. doi:10.1093/ndt/gfv089

50 Li L, Yang W, Astor BC, *et al.* Competing Risk Modeling: Time to Put it in Our Standard
Analytical Toolbox. *J Am Soc Nephrol* 2019;**30**:2284–6. doi:10.1681/ASN.2019101011

51 Wolkewitz M, Cooper BS, Bonten MJM, *et al.* Interpreting and comparing risks in the
presence of competing events. *BMJ* 2014;**349**:g5060. doi:10.1136/bmj.g5060

52 Ravani P, Fiocco M, Liu P, *et al.* Influence of Mortality on Estimating the Risk of Kidney
Failure in People with Stage 4 CKD. *J Am Soc Nephrol JASN* 2019;**30**:2219–27.
doi:10.1681/ASN.2019060640

53 Mehta P, Dhapte V, Kadam S, *et al.* Contemporary acupressure therapy: Adroit cure for
painless recovery of therapeutic ailments. *J Tradit Complement Med* 2017;**7**:251–63.
doi:10.1016/j.jtcme.2016.06.004

54   Alcalde-Rabanal JE, Lazo-González O, Nigenda G. [The health system of Peru]. *Salud*
Publica Mex 2011;**53 Suppl 2**:s243-254.

55   F S-M. [The national health system in Peru]. *Rev Peru Med Exp Salud Publica*
2014;**31**.https://pubmed.ncbi.nlm.nih.gov/25597729/ (accessed 23 Nov 2022).

794   Table 1. Baseline characteristics of the study population according to CKD stages.

Characteristic	CKD Stages 3a-3b-4 (n = 7,519)	CKD Stages 3b-4 (n = 2,798)
Sex		
Female	4,107 (54.6%)	1,398 (50.0%)
Male	3,412 (45.4%)	1,400 (50.0%)
Age (years)		
Mean (SD)	74.0 (10.2)	75.6 (10.6)
Median (IQR)	75.0 (68.0 - 81.0)	77.0 (70.0 - 83.0)
Range	23.0 - 97.0	23.0 - 97.0
Hypertension	4,486 (59.7%)	1,636 (58.5%)
Diabetes Mellitus	1,845 (24.5%)	674 (24.1%)
Persistent albuminuria categories		
A1	4,772 (63.5%)	1,494 (53.4%)
A2	2,018 (26.8%)	860 (30.7%)
A3	729 (9.7%)	444 (15.9%)
GFR categories		
G3a	4,721 (62.8%)	
G3b	2,207 (29.4%)	2,207 (78.9%)
G4	591 (7.9%)	591 (21.1%)
CKD KDIGO classification		
Moderately increased risk	3,278 (43.6%)	
High risk	2,460 (32.7%)	1,302 (46.5%)
Very high risk	1,781 (23.7%)	1,496 (53.5%)
Serum Creatinine (mg/dL)		
Mean (SD)	1.4 (0.4)	1.7 (0.5)
Median (IQR)	1.3 (1.1 - 1.5)	1.6 (1.4 - 1.9)
Range	0.8 - 3.9	1.1 - 3.9
eGFR (ml/min/1.73m^2)		
Mean (SD)	46.2 (9.8)	35.7 (7.3)
Median (IQR)	48.7 (40.4 - 53.8)	37.3 (31.4 - 41.7)
Range	15.0 - 60.0	15.0 - 45.0
ACR (mg/g)		
Mean (SD)	248.6 (3,044.4)	334.1 (3,050.8)
Median (IQR)	14.6 (4.5 - 66.1)	26.0 (6.5 - 153.8)
Range	0.0 - 144,870.6	0.0 - 144,870.6
Urine Albumin (mg/ml)		
Mean (SD)	8.3 (28.3)	13.1 (36.3)
Median (IQR)	1.0 (0.3 - 4.0)	1.7 (0.4 - 10.1)
Range	0.0 - 658.0	0.0 - 658.0
Urine Creatinine (mg/dl)		
Mean (SD)	72.4 (47.5)	71.4 (47.0)
Median (IQR)	63.3 (41.3 - 86.0)	64.9 (43.3 - 85.0)
Range	0.1 - 722.1	0.7 - 722.1
Death at 2 years*	640 (8.5%)	358 (12.8%)
Outcome at 2 years		
Alive w/o Kidney Failure	6,842 (91.0%)	2,410 (86.1%)
Death w/o Kidney Failure	563 (7.5%)	300 (10.7%)
Kidney Failure	114 (1.5%)	88 (3.1%)

Death at 5 years*	1,539 (20.5%)	784 (28.0%)
Outcome at 5 years		
Alive w/o Kidney Failure	5,880 (78.2%)	1,933 (69.1%)
Death w/o Kidney Failure	1,400 (18.6%)	683 (24.4%)
Kidney Failure	239 (3.2%)	182 (6.5%)

795 SD: standard deviation, IQR: interquartile range, ACR: urine albumin to creatinine ratio, eGFR: glomerular filtration
796 rate estimated by CKD-EPI formula
797 * Death after or before kidney failure
798
799

Table 2. Performance measures of KFRE in the external dataset of patients with CKD stages 3a-3b-4 and 3b-4.

Validation aspect and performance measure	CKD Stages 3a-3b-4		CKD Stages 3b-4	
	t = 2 year	t = 5 year	t = 2 year	t = 5 year
Calibration				
Average predicted risk	0.96%	3.18%	2.36%	7.66%
Average observed risk (95% CI)	1.52% (1.24% to 1.79%)	3.37% (2.95% to 3.8%)	3.15% (2.5% to 3.79%)	6.86% (5.89% to 7.84%)
O/E ratio (95% CI)	1.57 (1.39 to 1.76)	1.06 (0.93 to 1.19)	1.33 (1.13 to 1.54)	0.9 (0.75 to 1.04)
Calibration intercept (95% CI)	0.18 (-0.1 to 0.45)	-0.26 (-0.45 to -0.07)	0.16 (-0.12 to 0.44)	-0.29 (-0.48 to -0.1)
Calibration slope (95% CI)	0.79 (0.61 to 0.96)	0.75 (0.65 to 0.86)	0.82 (0.6 to 1.03)	0.79 (0.66 to 0.92)
Discrimination				
C-index up to t-years (95% CI)	0.853 (0.812 to 0.892)	0.845 (0.818 to 0.872)	0.848 (0.803 to 0.885)	0.827 (0.796 to 0.857)
C/D AUC, at t years (95% CI)	0.855 (0.816 to 0.895)	0.847 (0.819 to 0.875)	0.853 (0.811 to 0.895)	0.836 (0.803 to 0.869)

CKD: chronic kidney disease, t: time, O/E: Observed versus expected outcome ratio %: percentage, 95%CI: 95% confidence interval, C-index: truncated agreement index, C/D AUC-td: area under ROC curves time dependent on cumulative sensitivity and dynamic specificity.

Figure 1. Study flowchart.

Figure 2. Cumulative incidence function curves for kidney failure (sky-blue line) and death before kidney failure (red line) in patients with (A) CKD stages 3a-3b-4 and (B) CKD stages 3b-4.

CKD: Chronic Kidney Disease.

Figure 3. Calibration curves for each group and prediction horizon.

The x-axis shows the risk predicted by the KFRE model, and the y-axis represents the observed risk estimated using the cumulative incidence function to consider the competing risk of death without kidney failure. CKD: Chronic Kidney Disease.

Section/Topic			Checklist Item	Page
Title and abstract				
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	2
Introduction				
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	4-5
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	5
Methods				
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	5
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	5, 7
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	5
	5b	D;V	Describe eligibility criteria for participants.	5
	5c	D;V	Give details of treatments received, if relevant.	NA
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	7
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	NA
Predictors	7a	D;V	Clearly define all predictors used in developing the multivariable prediction model, including how and when they were measured.	6
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	NA
Sample size	8	D;V	Explain how the study size was arrived at.	6
Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	9
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	NA
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	NA
	10c	V	For validation, describe how the predictions were calculated.	6-7
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	8-9
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	NA
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	NA
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	Supplementary Material, Table S13 (page 17)
Results				
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	9
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	9-10
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	Supplementary Material, Table S13 (page 17)
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	NA
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	NA
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	NA
	15b	D	Explain how to use the prediction model.	NA
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	10-12
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	NA
Discussion				
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	16-17
Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	13-15
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	13-18

Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	17-18
Other information				
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Supplementary PDF and Code in Github repo
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	19

*Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

SUPPLEMENTARY MATERIAL

CONTENTS

1. SUPPLEMENTARY METHODS

1.1. KFRE equations validated externally by this study

This study performed external validation of the recalibrated equations for the non-North American population, which are available on page nine of the study supplementary material by *Tangri N, et al* (1) and were recommended as preferable by the article. These equations are implemented in the following web app: https://kidneyfailurerisk.com/. The equations we validated are shown in **Table S1**.

Table S1. KFRE equations externally validated by the study

Prediction horizons	Original regional equation calibrated for predicted risk of kidney failure
2-years	$1 - 0.9832^{e^{\left(-0.2201\times\left(\frac{age}{10}-7.036\right)+0.2467\times(male-0.5642)-0.5567\times\left(\frac{eGFR}{5}-7.222\right)+0.4510\times(\log(ACR)-5.137)\right)}}$
5-years	$1 - 0.9365^{e^{\left(-0.2201\times\left(\frac{age}{10}-7.036\right)+0.2467\times(male-0.5642)-0.5567\times\left(\frac{eGFR}{5}-7.222\right)+0.4510\times(\log(ACR)-5.137)\right)}}$

Source: Tangri N, et al. (1)

1.2. Variables

Table S2. Coding of variables

Variable	Coding
age	integer number that indicates the age in completed years
male	1 = male; 0 = female
eGFR_ckdepi	estimated glomerular filtration rate obtained by CKD-EPI formula in ml/min/1.73m^2
acr	albumin-to-creatinine ratio in mg/g

1.3. 2009 CKD Epidemiology Collaboration (CKD-EPI) formula for eGFR

$$eGFR \;=\; A \times (SCr/B)^C \times 0.993^{age} \times (1.159\; if\; black)$$

Where $A, B, and\ C$ are the following:

Female		Male	
$SCr \leq 0.7$	$A = 144$ $B = 0.7$ $C = -0.329$	$SCr \leq 0.9$	$A = 141$ $B = 0.9$ $C = -0.411$
$SCr > 0.7$	$A = 144$ $B = 0.7$ $C = -1.209$	$SCr > 0.9$	$A = 141$ $B = 0.9$ $C = -1.209$

2. SUPPLEMENTARY TABLES

Table S3. Baseline characteristics of study patients at CKD Stages 3a, 3b, or 4 for all predictors, stratified by 2- and 5-year outcomes.

Characteristic	2-years		5-years	
	No kidney failure (n = 7,405)	Kidney failure (n = 114)	No kidney failure (n = 7,280)	Kidney failure (n = 239)
Sex				
Female	4,062 (54.9%)	45 (39.5%)	4,015 (55.2%)	92 (38.5%)
Male	3,343 (45.1%)	69 (60.5%)	3,265 (44.8%)	147 (61.5%)
Age (years)				
Mean (SD)	74.1 (10.2)	66.6 (11.7)	74.2 (10.1)	66.5 (12.5)
Median (IQR)	75.0 (68.0, 81.0)	67.0 (59.2, 74.0)	75.0 (68.0, 82.0)	67.0 (59.0, 75.0)
Range	23.0, 97.0	36.0, 88.0	23.0, 97.0	26.0, 94.0
Hypertension	4,421 (59.7%)	65 (57.0%)	4,339 (59.6%)	147 (61.5%)
Diabetes Mellitus	1,796 (24.3%)	49 (43.0%)	1,743 (23.9%)	102 (42.7%)
Persistent albuminuria categories				
A1	4,749 (64.1%)	23 (20.2%)	4,725 (64.9%)	47 (19.7%)
A2	1,984 (26.8%)	34 (29.8%)	1,941 (26.7%)	77 (32.2%)
A3	672 (9.1%)	57 (50.0%)	614 (8.4%)	115 (48.1%)
GFR categories				
G3a	4,695 (63.4%)	26 (22.8%)	4,664 (64.1%)	57 (23.8%)
G3b	2,171 (29.3%)	36 (31.6%)	2,126 (29.2%)	81 (33.9%)
G4	539 (7.3%)	52 (45.6%)	490 (6.7%)	101 (42.3%)
CKD KDIGO classification				
Moderately increased risk	3,266 (44.1%)	12 (10.5%)	3,256 (44.7%)	22 (9.2%)
High risk	2,448 (33.1%)	12 (10.5%)	2,429 (33.4%)	31 (13.0%)
Very high risk	1,691 (22.8%)	90 (78.9%)	1,595 (21.9%)	186 (77.8%)
Serum Creatinine (mg/dL)				
Mean (SD)	1.4 (0.4)	2.0 (0.7)	1.3 (0.4)	2.0 (0.7)
Median (IQR)	1.3 (1.1, 1.5)	1.9 (1.5, 2.5)	1.3 (1.1, 1.5)	1.9 (1.5, 2.4)
Range	0.8, 3.8	1.0, 3.9	0.8, 3.8	0.9, 3.9

eGFR (ml/min/1.73m2)				
Mean (SD)	46.4 (9.6)	33.7 (12.5)	46.6 (9.4)	34.5 (12.4)
Median (IQR)	48.9 (40.8, 53.9)	31.7 (23.2, 42.8)	49.0 (41.1, 53.9)	33.0 (23.5, 44.2)
Range	15.0, 60.0	15.4, 59.8	15.1, 60.0	15.0, 59.8
ACR (mg/g)				
Mean (SD)	235.5 (3,059.4)	1,101.7 (1,614.1)	229.3 (3,083.4)	836.1 (1,283.1)
Median (IQR)	14.2 (4.4, 62.7)	302.0 (52.5, 1,663.9)	14.0 (4.4, 59.4)	270.9 (51.2, 992.4)
Range	0.0, 144,870.6	2.5, 7,462.7	0.0, 144,870.6	0.2, 7,462.7
Urine Albumin (mg/ml)				
Mean (SD)	7.6 (26.5)	52.1 (73.5)	7.1 (25.7)	44.0 (62.3)
Median (IQR)	0.9 (0.3, 3.7)	16.0 (4.3, 71.6)	0.9 (0.3, 3.5)	15.3 (3.4, 56.5)
Range	0.0, 658.0	0.2, 348.1	0.0, 658.0	0.0, 348.1
Urine Creatinine (mg/dl)				
Mean (SD)	72.5 (47.7)	64.8 (33.7)	72.4 (47.0)	69.8 (61.0)
Median (IQR)	63.4 (41.4, 86.5)	59.6 (39.6, 85.0)	63.5 (41.3, 86.6)	58.7 (41.0, 85.0)
Range	0.1, 722.1	6.4, 218.6	0.1, 620.1	6.4, 722.1
Death at 2 years*	563 (7.6%)	77 (67.5%)	563 (7.7%)	77 (32.2%)
Outcome at 2 years				
Alive w/o Kidney Failure	6,842 (92.4%)	0 (0.0%)	6,717 (92.3%)	125 (52.3%)
Death w/o Kidney Failure	563 (7.6%)	0 (0.0%)	563 (7.7%)	0 (0.0%)
Kidney Failure	0 (0.0%)	114 (100.0%)	0 (0.0%)	114 (47.7%)
Death at 5 years*	1,462 (19.7%)	77 (67.5%)	1,400 (19.2%)	139 (58.2%)
Outcome at 5 years				
Alive w/o Kidney Failure	5,880 (79.4%)	0 (0.0%)	5,880 (80.8%)	0 (0.0%)
Death w/o Kidney Failure	1,400 (18.9%)	0 (0.0%)	1,400 (19.2%)	0 (0.0%)
Kidney Failure	125 (1.7%)	114 (100.0%)	0 (0.0%)	239 (100.0%)

IQR: interquartile range, ACR: urine albumin to creatinine ratio, eGFR: glomerular filtration rate estimated by CKD-EPI formula

* Death after or before kidney failure

Table S4. Baseline characteristics of study patients at CKD Stages 3b or 4 for all predictors, stratified by 2- and 5-year outcomes.

Characteristic	2-years		5-years	
	No kidney failure (n = 2,710)	Kidney failure (n = 88)	No kidney failure (n = 2,616)	Kidney failure (n = 182)
Sex				
Female	1,363 (50.3%)	35 (39.8%)	1,329 (50.8%)	69 (37.9%)
Male	1,347 (49.7%)	53 (60.2%)	1,287 (49.2%)	113 (62.1%)
Age (years)				
Mean (SD)	75.9 (10.4)	66.1 (12.1)	76.2 (10.2)	66.9 (12.4)
Median (IQR)	77.0 (70.0, 83.0)	67.0 (59.0, 74.0)	77.0 (70.0, 83.0)	67.0 (59.2, 75.0)
Range	23.0, 97.0	36.0, 88.0	23.0, 97.0	26.0, 94.0
Hypertension	1,581 (58.3%)	55 (62.5%)	1,517 (58.0%)	119 (65.4%)
Diabetes Mellitus	635 (23.4%)	39 (44.3%)	596 (22.8%)	78 (42.9%)
Persistent albuminuria categories				
A1	1,483 (54.7%)	11 (12.5%)	1,469 (56.2%)	25 (13.7%)
A2	830 (30.6%)	30 (34.1%)	798 (30.5%)	62 (34.1%)
A3	397 (14.6%)	47 (53.4%)	349 (13.3%)	95 (52.2%)
GFR categories				
G3a	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
G3b	2,171 (80.1%)	36 (40.9%)	2,126 (81.3%)	81 (44.5%)
G4	539 (19.9%)	52 (59.1%)	490 (18.7%)	101 (55.5%)
CKD KDIGO classification				
Moderately increased risk	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
High risk	1,294 (47.7%)	8 (9.1%)	1,286 (49.2%)	16 (8.8%)
Very high risk	1,416 (52.3%)	80 (90.9%)	1,330 (50.8%)	166 (91.2%)
Serum Creatinine (mg/dL)				
Mean (SD)	1.7 (0.4)	2.3 (0.6)	1.7 (0.4)	2.2 (0.6)
Median (IQR)	1.6 (1.4, 1.9)	2.1 (1.8, 2.5)	1.6 (1.4, 1.8)	2.1 (1.7, 2.5)
Range	1.1, 3.8	1.2, 3.9	1.1, 3.8	1.2, 3.9
eGFR (ml/min/1.73m^2)				
Mean (SD)	35.9 (7.1)	28.2 (8.1)	36.1 (7.0)	29.0 (8.3)
Median (IQR)	37.6 (31.8, 41.8)	26.9 (21.6, 34.9)	37.8 (32.1, 41.9)	28.3 (22.4, 35.4)
Range	15.0, 45.0	15.4, 43.8	15.1, 45.0	15.0, 44.9
ACR (mg/g)				
Mean (SD)	306.8 (3,082.4)	1,172.8 (1,631.1)	296.0 (3,133.9)	881.4 (1,272.2)
Median (IQR)	24.6 (6.3, 145.4)	367.7 (149.1, 1,811.8)	23.3 (6.1, 131.2)	334.6 (143.8, 1,076.5)

Range	0.0, 144,870.6	2.5, 7,462.7	0.0, 144,870.6	1.4, 7,462.7
Urine Albumin (mg/ml)				
Mean (SD)	11.7 (33.3)	56.1 (77.1)	10.7 (32.2)	47.4 (64.4)
Median (IQR)	1.5 (0.4, 8.7)	16.3 (8.9, 66.6)	1.4 (0.4, 7.7)	16.5 (8.6, 60.3)
Range	0.0, 658.0	0.2, 348.1	0.0, 658.0	0.1, 348.1
Urine Creatinine (mg/dl)				
Mean (SD)	71.7 (47.4)	62.1 (33.5)	71.7 (45.8)	68.3 (61.8)
Median (IQR)	65.1 (43.7, 85.0)	55.3 (38.1, 85.0)	65.4 (43.9, 85.0)	58.0 (40.1, 85.0)
Range	0.7, 722.1	6.4, 218.6	0.7, 620.1	6.4, 722.1
Death at 2 years*	300 (11.1%)	58 (65.9%)	300 (11.5%)	58 (31.9%)
Outcome at 2 years				
Alive w/o Kidney Failure	2,410 (88.9%)	NA	2,316 (88.5%)	94 (51.6%)
Death w/o Kidney Failure	300 (11.1%)	NA	300 (11.5%)	NA
Kidney Failure	NA	88 (100.0%)	NA	88 (48.4%)
Death at 5 years*	726 (26.8%)	58 (65.9%)	683 (26.1%)	101 (55.5%)
Outcome at 5 years				
Alive w/o Kidney Failure	1,933 (71.3%)	0 (0.0%)	1,933 (73.9%)	0 (0.0%)
Death w/o Kidney Failure	683 (25.2%)	0 (0.0%)	683 (26.1%)	NA
Kidney Failure	94 (3.5%)	88 (100.0%)	NA	182 (100.0%)

IQR: interquartile range, ACR: urine albumin to creatinine ratio, eGFR: glomerular filtration rate estimated by CKD-EPI formula. NA: not applicable
* Death after or before kidney failure

Table S5. Baseline characteristics and frequency of outcomes in the study population according to CKD stages.

Characteristic	G3a (n = 4,721)	G3b (n = 2,207)	G4 (n = 591)
Sex			
Female	2,709 (57.4%)	1,102 (49.9%)	296 (50.1%)
Male	2,012 (42.6%)	1,105 (50.1%)	295 (49.9%)
Age (years)			
Mean (SD)	73.1 (9.9)	76.0 (10.2)	73.9 (11.8)
Median (IQR)	74.0 (67.0 - 80.0)	77.0 (70.0 - 83.0)	75.0 (67.0 - 83.0)
Range	23.0 - 97.0	26.0 - 97.0	23.0 - 95.0
Hypertension	2,850 (60.4%)	1,295 (58.7%)	341 (57.7%)
Diabetes Mellitus	1,171 (24.8%)	521 (23.6%)	153 (25.9%)
Persistent albuminuria categories			
A1	3,278 (69.4%)	1,302 (59.0%)	192 (32.5%)
A2	1,158 (24.5%)	632 (28.6%)	228 (38.6%)
A3	285 (6.0%)	273 (12.4%)	171 (28.9%)
CKD KDIGO classification			
Moderately increased risk	3,278 (69.4%)	0 (0.0%)	0 (0.0%)
High risk	1,158 (24.5%)	1,302 (59.0%)	0 (0.0%)
Very high risk	285 (6.0%)	905 (41.0%)	591 (100.0%)
Serum Creatinine (mg/dL)			
Mean (SD)	1.2 (0.2)	1.5 (0.2)	2.3 (0.5)
Median (IQR)	1.1 (1.0 - 1.3)	1.5 (1.3 - 1.7)	2.3 (1.9 - 2.6)
Range	0.8 - 1.9	1.1 - 2.4	1.5 - 3.9
eGFR (ml/min/1.73m^2)			
Mean (SD)	52.5 (3.9)	38.8 (4.2)	24.2 (4.1)
Median (IQR)	52.6 (49.4 - 55.6)	39.3 (35.3 - 42.4)	24.7 (21.2 - 27.7)
Range	45.0 - 60.0	30.0 - 45.0	15.0 - 30.0
ACR (mg/g)			
Mean (SD)	198.0 (3,039.8)	302.6 (3,386.3)	451.7 (1,109.7)
Median (IQR)	10.8 (3.9 - 41.5)	20.3 (5.3 - 100.1)	127.2 (17.7 - 405.2)
Range	0.0 - 137,672.1	0.0 - 144,870.6	0.1 - 18,259.2
Urine Albumin (mg/ml)			
Mean (SD)	5.5 (21.8)	10.0 (31.4)	25.0 (48.8)
Median (IQR)	0.7 (0.2 - 2.4)	1.3 (0.3 - 5.8)	7.4 (1.3 - 20.9)
Range	0.0 - 548.0	0.0 - 658.0	0.0 - 383.0
Urine Creatinine (mg/dl)			
Mean (SD)	72.9 (47.9)	71.3 (46.0)	72.0 (50.7)
Median (IQR)	62.4 (40.4 - 88.1)	64.8 (43.0 - 85.0)	65.3 (44.6 - 85.0)
Range	0.1 - 438.3	0.8 - 620.1	0.7 - 722.1
Death at 2 years*	282 (6.0%)	230 (10.4%)	128 (21.7%)
Outcome at 2 years			
Alive w/o Kidney Failure	4,432 (93.9%)	1,965 (89.0%)	445 (75.3%)

Death w/o Kidney Failure	263 (5.6%)	206 (9.3%)	94 (15.9%)
Kidney Failure	26 (0.6%)	36 (1.6%)	52 (8.8%)
Death at 5 years*	755 (16.0%)	555 (25.1%)	229 (38.7%)
Outcome at 5 years			
Alive w/o Kidney Failure	3,947 (83.6%)	1,622 (73.5%)	311 (52.6%)
Death w/o Kidney Failure	717 (15.2%)	504 (22.8%)	179 (30.3%)
Kidney Failure	57 (1.2%)	81 (3.7%)	101 (17.1%)

IQR: interquartile range, ACR: urine albumin to creatinine ratio, eGFR: glomerular filtration rate estimated by CKD-EPI formula

* Death after or before kidney failure

Table S6. Distribution of CKD 3a-4 patients included in the analysis across 17 health facilities of the EsSalud Rebagliati Network

Healthcare center*	Overall (n = 7,519)	Outcome		
		Alive w/o Kidney Failure (n = 5,880)	Death w/o Kidney Failure (n = 1,400)	Kidney Failure (n = 239)
Healthcare №1	74 (100.0%)	48 (64.9%)	18 (24.3%)	8 (10.8%)
Healthcare №2	58 (100.0%)	52 (89.7%)	6 (10.3%)	0 (0.0%)
Healthcare №3	403 (100.0%)	319 (79.2%)	73 (18.1%)	11 (2.7%)
Healthcare №4	287 (100.0%)	204 (71.1%)	71 (24.7%)	12 (4.2%)
Healthcare №5	308 (100.0%)	242 (78.6%)	53 (17.2%)	13 (4.2%)
Healthcare №6	1,471 (100.0%)	1,088 (74.0%)	298 (20.3%)	85 (5.8%)
Healthcare №7	34 (100.0%)	20 (58.8%)	11 (32.4%)	3 (8.8%)
Healthcare №8	1,032 (100.0%)	858 (83.1%)	160 (15.5%)	14 (1.4%)
Healthcare №9	207 (100.0%)	158 (76.3%)	42 (20.3%)	7 (3.4%)
Healthcare №10	258 (100.0%)	179 (69.4%)	73 (28.3%)	6 (2.3%)
Healthcare №11	77 (100.0%)	71 (92.2%)	5 (6.5%)	1 (1.3%)
Healthcare №12	1,289 (100.0%)	1,058 (82.1%)	202 (15.7%)	29 (2.2%)
Healthcare №13	679 (100.0%)	497 (73.2%)	166 (24.4%)	16 (2.4%)
Healthcare №14	752 (100.0%)	586 (77.9%)	143 (19.0%)	23 (3.1%)
Healthcare №15	454 (100.0%)	381 (83.9%)	64 (14.1%)	9 (2.0%)
Healthcare №16	102 (100.0%)	90 (88.2%)	10 (9.8%)	2 (2.0%)
Healthcare №17	34 (100.0%)	29 (85.3%)	5 (14.7%)	0 (0.0%)

* For privacy reasons, the name of the current healthcare provider is not disclosed. However, we can provide the names internally if the request is reasonable and appropriate mechanisms are in place to ensure the protection of data privacy.

Table S7. Distribution of CKD 3b-4 patients included in the analysis across 17 health facilities of the EsSalud Rebagliati Network.

Healthcare center*	Overall (n = 2,798)	Outcome		
		Alive w/o Kidney Failure (n = 1,933)	Death w/o Kidney Failure (n = 683)	Kidney Failure (n = 182)
Healthcare №1	26 (100.0%)	10 (38.5%)	10 (38.5%)	6 (23.1%)
Healthcare №2	12 (100.0%)	8 (66.7%)	4 (33.3%)	0 (0.0%)
Healthcare №3	129 (100.0%)	87 (67.4%)	32 (24.8%)	10 (7.8%)
Healthcare №4	113 (100.0%)	68 (60.2%)	35 (31.0%)	10 (8.8%)
Healthcare №5	115 (100.0%)	81 (70.4%)	24 (20.9%)	10 (8.7%)
Healthcare №6	921 (100.0%)	644 (69.9%)	212 (23.0%)	65 (7.1%)
Healthcare №7	22 (100.0%)	11 (50.0%)	8 (36.4%)	3 (13.6%)
Healthcare №8	271 (100.0%)	194 (71.6%)	67 (24.7%)	10 (3.7%)
Healthcare №9	70 (100.0%)	47 (67.1%)	17 (24.3%)	6 (8.6%)
Healthcare №10	90 (100.0%)	59 (65.6%)	28 (31.1%)	3 (3.3%)
Healthcare №11	15 (100.0%)	13 (86.7%)	1 (6.7%)	1 (6.7%)
Healthcare №12	408 (100.0%)	294 (72.1%)	93 (22.8%)	21 (5.1%)
Healthcare №13	216 (100.0%)	134 (62.0%)	70 (32.4%)	12 (5.6%)
Healthcare №14	215 (100.0%)	152 (70.7%)	47 (21.9%)	16 (7.4%)
Healthcare №15	144 (100.0%)	106 (73.6%)	30 (20.8%)	8 (5.6%)
Healthcare №16	23 (100.0%)	18 (78.3%)	4 (17.4%)	1 (4.3%)
Healthcare №17	8 (100.0%)	7 (87.5%)	1 (12.5%)	0 (0.0%)

* For privacy reasons, the name of the current healthcare provider is not disclosed. However, we can provide the names internally if the request is reasonable and appropriate mechanisms are in place to ensure the protection of data privacy.

Table S8. Cumulative incidence of kidney failure and death without kidney failure in patients with CKD stages 3a-3b-4.

Year	Kidney failure		Death without kidney failure	
	%	95% CI	%	95% CI
1-year	0.68%	(0.49% to 0.86%)	3.82%	(3.38% to 4.25%)
2-year	1.52%	(1.24% to 1.79%)	7.49%	(6.89% to 8.08%)
3-year	2.23%	(1.9% to 2.57%)	11.2%	(10.48% to 11.91%)
4-year	2.88%	(2.5% to 3.26%)	15.58%	(14.75% to 16.41%)
5-year	3.37%	(2.95% to 3.8%)	20.46%	(19.48% to 21.42%)

%: observed risk estimated utilising the cumulative incidence function with the Aalen-Johansen estimator to account for competing risk; CI: confidence interval

Table S9. Cumulative incidence of kidney failure and death without kidney failure in patients with CKD stages 3b-4.

Year	Kidney failure		Death without kidney failure	
	%	95% CI	%	95% CI
1-year	1.54%	(1.08% to 1.99%)	6%	(5.12% to 6.88%)
2-year	3.15%	(2.5% to 3.79%)	10.72%	(9.57% to 11.86%)
3-year	4.72%	(3.93% to 5.5%)	15.51%	(14.16% to 16.84%)
4-year	6.02%	(5.12% to 6.9%)	21.03%	(19.48% to 22.55%)
5-year	6.86%	(5.89% to 7.83%)	26.59%	(24.84% to 28.3%)

%: observed risk estimated utilising the cumulative incidence function with the Aalen-Johansen estimator to account for competing risk; CI: confidence interval; CI: confidence interval

Table S10. Summary of ACR, 2-year and 5-year predicted risks of kidney failure according to KFRE before and after winsorising the 1% and 99% extreme values of ACR.

	Original data	Winsorised outliers in ACR.
Characteristic	N = 7,519	N = 7,519
ACR (mg/g)		
Mean ± SD	248.620 ± 3,044.427	144.053 ± 437.405
Median (IQR)	14.634 (4.484, 66.114)	14.634 (4.484, 66.114)
Range	0.002, 144,870.588	0.236, 3,195.727
Predicted risk of kidney failure to 2 years (%)		
Mean ± SD	0.963 ± 3.263	0.944 ± 3.155
Median (IQR)	0.131 (0.057, 0.429)	0.131 (0.057, 0.429)
Range	0.001, 53.657	0.006, 53.657
Predicted risk of kidney failure to 5 years (%)		
Mean ± SD	3.182 ± 8.913	3.138 ± 8.760
Median (IQR)	0.507 (0.220, 1.650)	0.508 (0.221, 1.649)
Range	0.004, 94.911	0.024, 94.911

SD: standard deviation, IQR: interquartile range, ACR: urine albumin to creatinine ratio

Table S11. Performance measures of KFRE in the external dataset of patients with CKD stages 3a-3b-4 and 3b-4 following the application of winsorisation to the ACR variable and the subsequent recalculation of predicted risks using the Kidney Failure Risk Equation (KFRE).

Validation aspect and performance measure	CKD Stages 3a-3b-4		CKD Stages 3b-4	
	t = 2 year	t = 5 year	t = 2 year	t = 5 year
Calibration				
Average predicted risk	0.94%	3.14%	2.32%	7.58%
Average observed proportion (95% CI)	1.52% (1.24% to 1.79%)	3.37% (2.95% to 3.8%)	3.15% (2.5% to 3.79%)	6.86% (5.89% to 7.84%)
O/E ratio (95% CI)	1.61 (1.42 to 1.79)	1.08 (0.95 to 1.2)	1.35 (1.15 to 1.56)	0.91 (0.76 to 1.05)
Calibration intercept (95% CI)	0.21 (-0.06 to 0.49)	-0.23 (-0.41 to -0.04)	0.19 (-0.09 to 0.47)	-0.26 (-0.45 to -0.07)
Calibration slope (95% CI)	0.79 (0.61 to 0.97)	0.77 (0.66 to 0.87)	0.82 (0.61 to 1.04)	0.8 (0.67 to 0.94)
Discrimination				
C-index up to t-years (95% CI)	0.853 (0.812 to 0.893)	0.845 (0.818 to 0.872)	0.848 (0.804 to 0.885)	0.828 (0.797 to 0.857)
C/D AUC, at t years (95% CI)	0.855 (0.816 to 0.895)	0.848 (0.82 to 0.875)	0.854 (0.812 to 0.896)	0.837 (0.804 to 0.87)

CKD: chronic kidney disease, t: time, O/E: Observed versus expected outcome ratio %: percentage, 95%CI: 95% confidence interval, C-index: truncated agreement index, C/D AUC-td: area under ROC curves time dependent on cumulative sensitivity and dynamic specificity.

Table S12. Performance measures of KFRE in the external dataset of patients with CKD stages 3a-3b-4 and 3b-4, without considering competing risks.

Validation aspect and performance measure	CKD Stages 3a-3b-4		CKD Stages 3b-4	
	t = 2 year	t = 5 year	t = 2 year	t = 5 year
Calibration				
Average predicted risk	0.96%	3.18%	2.36%	7.66%
Average observed proportion	1.58%	3.72%	3.35%	7.88%
O/E ratio (95% CI)	1.64 (1.37 to 1.97)	1.17 (1.03 to 1.33)	1.42 (1.15 to 1.75)	1.03 (0.89 to 1.19)
Calibration slope (95% CI)	0.79 (0.72 to 0.85)	0.79 (0.72 to 0.85)	0.83 (0.74 to 0.93)	0.83 (0.74 to 0.93)
Discrimination				
Harrell C (95% CI)	0.856 (0.817 to 0.895)	0.856 (0.83 to 0.883)	0.85 (0.809 to 0.891)	0.839 (0.809 to 0.869)
Uno C (95% CI)	0.856 (0.817 to 0.895)	0.851 (0.825 to 0.878)	0.851 (0.81 to 0.892)	0.832 (0.801 to 0.864)
C/D AUC, at t years (95% CI)	0.861 (0.822 to 0.9)	0.86 (0.832 to 0.887)	0.86 (0.818 to 0.901)	0.846 (0.812 to 0.879)

CKD: chronic kidney disease, t: time, O/E: Observed versus expected outcome ratio %: percentage, 95%CI: 95% confidence interval, C/D AUC-td: area under ROC curves time dependent on cumulative sensitivity and dynamic specificity.

Table S13. Comparisons of characteristics of original cohort that recalibrated Non North American version of KFRE and our study population

Characteristics	Original Study (Non-North American population)	Current study	
		CKD Stages 3a-4	CKD Stages 3b-4
Numbef of participants	103753	7519	2798
F/U Time, years, Median (IQR)	4 (3, 6)	4.9 (3.5, 5.9)	4.6 (3.2, 5.8)
Age, years (SD)	71 (12)	74 (10.2)	75.6 (10.6)
Male, n (%)	46632 (45%)	3412 (45.4%)	1400 (50%)
Black ethnicity, n (%)	393 (0.4%)	0 (0%)	0 (0%)
eGFR, ml/min/1.73m^2 (SD)	47 (12)	46.2 (9.8)	35.7 (7.3)
Albuminuria, n (%)	24962 (34%)	2747 (36.5%)	1304 (46.6%)
Kidney Failure Incidence (per 1000 py)	9.2	7.4	16.1

F/U: follow-up; eGFR: glomerular filtration rate estimated by CKD-EPI formula

3. SUPPLEMENTARY FIGURES

Figure S1. Distribution of the 2-year and 5-year predicted risk estimated by KFRE equation according to kidney failure outcomes.

Figure S2. Distribution of the four KFRE equation variables in CKD 3-4 and CKD 3b-4 patients.

(A) age in years, (B) estimated glomerular filtration rate (eGFR) according to the CKD-EPI formula, (C) urine albumin to creatinine ratio (ACR) expressed in the original scale, and (D) natural logarithm scale for improved comparison of distributions.

Figure S3. Distribution of ACR in CKD 3-4 and CKD 3b-4 patients before and after winsorising the 1% and 99% extreme values of ACR.

Figure S4. Distribution of the recalculated 2-year and 5-year predicted risk estimated by the KFRE equation after winsorising the 1% and 99% extreme values of ACR.

Figure S5. Calibration curves for each group and prediction horizon following the application of winsorisation to the ACR variable and the subsequent recalculation of predicted risks using the Kidney Failure Risk Equation (KFRE).

Figure S6. Differences between Kaplan-Meier (KM) and cumulative incidence functions (CIF) estimates of the observed outcome risks in the presence of competing events, in CKD 3a-4 and CKD 3b-4 patients.

Figure S7. Calibration curves for each group and prediction horizon, disregarding competing risks.

4. REFERENCES

1. Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, et al. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. JAMA [Internet]. 12 de enero de 2016 [citado 30 de enero de 2020];315(2):164-74. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2481005

A CKD Stages 3a-3b-4

Number at risk (number of events)

7519 (0)	7181 (338)	6842 (677)	6509 (1010)	4893 (1349)	3549 (163!

B CKD Stages 3b-4

Number at risk (number of events)

2798 (0)	2587 (211)	2410 (388)	2232 (566)	1595 (736)	1161 (865